All In Biotech

NDA 021254 · Glaxo Grp LTD

Advair Hfa

Fluticasone Propionate, Salmeterol Xinafoate · Inhalation

Last checked: Nov 20, 2026Latest source record: Aug 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jun 8, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

738

240 Phase 3, 19 recruiting

FAERS reports

60,258

34,763 serious, 3,620 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 8, 2025.

ADVAIR HFA is indicated for treatment of asthma in adult and adolescent patients aged 12 years and older. ADVAIR HFA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta 2 -adrenergic agonist (LABA). Limitations of Use ADVAIR HFA is not indicated for the relief of acute bronchospasm. ADVAIR HFA is a combination of fluticasone propionate, an inhaled corticosteroid, and salmeterol, a long-acting beta 2 ‑adrenergic agonist (LABA), indicated for treatment of asthma in adult and adolescent patients aged 12 years and older. ( 1 ) Limitations of use: Not indicated for relief of acute bronchospasm. ( 1 )

Mechanism: ADVAIR HFA ADVAIR HFA contains both fluticasone propionate and salmeterol. The mechanisms of action described below for the individual components apply to ADVAIR HFA. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices of asthma. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ADVAIR HFA · FLUTICASONE PROPIONATE 0.115MG/INH; SALMETEROL XINAFOATE EQ 0.021MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription
  • ADVAIR HFA · FLUTICASONE PROPIONATE 0.23MG/INH; SALMETEROL XINAFOATE EQ 0.021MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription
  • ADVAIR HFA · FLUTICASONE PROPIONATE 0.045MG/INH; SALMETEROL XINAFOATE EQ 0.021MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.

All 738 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea10,067
  • asthma8,223
  • drug ineffective5,535
  • pneumonia4,989
  • cough4,984
  • wheezing4,239
  • fatigue3,968
  • headache3,663
  • malaise3,642
  • pain3,429
  • off label use2,872
  • nausea2,761

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004584
200550
20061,754
200736
2008479
20091,711
2010106
2011388
2012449
2013684
20146,553
20155,812
20166,163
20174,592
20184,515
20194,884
20204,812
20213,556
20222,972
20232,761
20243,075
20252,642
20261,678

Recalls

2 FDA enforcement reports for this application.

  • Oct 24, 2012 · Class III · Terminated

    Product Lacks Stability: These lots are being recalled due to the failure to meet the particle size distribution specification.

  • Oct 24, 2012 · Class III · Terminated

    Product Lacks Stability: These lots are being recalled due to the failure to meet the particle size distribution specification.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jul 27, 2026

    Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22). The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product...

  • To Be Discontinued · updated Jul 27, 2026

    Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22). The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product...

  • To Be Discontinued · updated Jul 27, 2026

    Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22). The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Advair HFA (Fluticasone Propion/Salmeterol)

2024 spending

$321M

Beneficiaries

200,081

715,505 claims

Per beneficiary

$1,602

$28.71 per unit

View as table
YearSpending
2020$313,758,155
2021$346,301,512
2022$384,716,839
2023$398,376,288
2024$320,587,780

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,187 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.